Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
Skip to content

Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry

Get report
  • There are no suggestions because the search field is empty.
Request a Demo
Request a Demo

Core Capabilities

Featured

Radar metrics
BLOG The market has changed: Frost & Sullivan's 2026 Radar shows who's leading it RapidAI Chief Business Officer David Stoffel, MD, MBA, breaks down what this recognition signals — and what it means for health systems planning their AI strategy for the years ahead LEARN MORE
Platform overview
Request a Demo

RADIOLOGY SUPPORT

Neurovascular

Cardiac + vascular

LIFE SCIENCES

Featured

Cognitive Burden index RapidAI 2025
BLOG Radiology’s real challenge Read about the reality of cognitive burden LEARN MORE
Solutions overview
Request a Demo

BUILT TO SUPPORT THE FULL SYSTEM

FEATURED

Resource_1600x900_C-Suite-Exec Insights_white paper
WHITE PAPER Empowering healthcare leaders with a deep clinical AI enterprise platform Learn how AI can address real-world challenges for administrators LEARN MORE
Overview
Request a Demo

Core Capabilities

Featured

Radiology Rewired podcast
PODCAST Season 1 available now Exploring how AI is transforming Radiology—one conversation at a time with clinicians and innovators LEARN MORE
Overview
Request a Demo

TRAINING & LEARNING

HELP & ASSISTANCE

Overview
Request a Demo

LEARN MORE ABOUT RAPIDAI

WORK WITH US

FEATURED

video thumbnail for dr Gregory Albers
VIDEO The story behind RapidAI Hear our founder, Greg Albers, MD, tell the history of how the company came to be Watch now
Company overview
Request a Demo
Press Release

Rapid ASPECTS First Neuroimaging Solution with CADx FDA Clearance

AI-Powered Stroke Imaging Solution First to Receive FDA Advanced CADx Clearance to Raise Reading Capabilities for Non-Expert Readers

Share to

AI-Powered Stroke Imaging Solution First to Receive FDA Advanced CADx Clearance to Raise Reading Capabilities for Non-Expert Readers

Menlo Park, Calif. — June 16, 2020 —RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid ASPECTS has received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category. Rapid ASPECTS is the only neuroimaging product shown to improve physicians’ interpretations of Non-Contrast CT (NCCT) scans using a standardized ASPECT score. Validated through the rigorous FDA process, the use of Rapid ASPECTS automated score combined with the physician’s review of the scan, improves the accuracy of the ASPECT score calculation which is particularly important for less experienced readers. Based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, Rapid ASPECTS uses a validated machine-learning algorithm to automatically identify the ASPECTS regions of the brain and generate an ASPECT score to indicate early signs of brain infarction on NCCT scans—helping physicians identify areas of irreversible brain injury. By automating and standardizing this process, Rapid ASPECTS helps stroke teams across hospital sites and referral networks quickly assess patient eligibility for thrombectomy—enabling faster triage and transfer decisions that facilitate better patient outcomes. “Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “In addition to helping stroke teams with faster triage and transfer decisions, Rapid ASPECTS also improves the accuracy of typical readers.” Rapid ASPECTS Provides: Standardized, predictive assessment: In a few minutes, Rapid ASPECTS automatically delivers a standardized ASPECT score—assisting physicians to quickly identify areas of irreversible injury and help determine a patient’s eligibility for thrombectomy. Validated Machine-Learning Intelligence: Rapid ASPECTS delivers fast measurements utilizing a sophisticated, machine-learning algorithm that has been validated in clinical research studies. Faster Triage or Transfer Decisions: Rapid ASPECTS supports collaboration between hospitals and specialists to make faster triage and transfer decisions for patients—helping to facilitate better patient care and outcomes. “The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, Senior Vice President of Regulatory and Clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.” RapidAI is the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. It is the only clinically validated platform available and the gold standard for advanced cerebrovascular imaging. Based on intelligence gained from over 650,000+ scans from more than 1,500 hospitals in over 50 countries, the artificial intelligence-based Rapid ® platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI. Already in use internationally, Rapid ASPECTS will be commercially available in the U.S. later this month. To learn more, visit rapidai.com/rapid-aspects.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com